Artelo Biosciences launches $6.53M ATM program; Craft Capital files FINRA claim for $880K

ARTELO BIOSCIENCES, INC.

Entered at-the-market offering agreement with H.C. Wainwright to sell up to $6.53M of common stock, with 3.0% commission.
Shelf registration (Form S-3) effective May 19, 2026; ATM prospectus supplement filed May 26, 2026.
Craft Capital Management filed FINRA arbitration claim alleging breach of right of first refusal; seeks $880K success fee, warrants valued at $880K, plus late fees.
Company terminated engagement with Craft on March 27, 2026 and closed private placement of ~$11M on March 30, 2026.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.95

ARTELO BIOSCIENCES, INC. entered into At The Market Offering Agreement with H.C. Wainwright & Co., LLC valued at up to an aggregate of $6,530,000 (effective 2026-05-26).

Action: entry
Agreement: atm program
Counterparty: H.C. Wainwright & Co., LLC
Value: up to an aggregate of $6,530,000
Effective: 2026-05-26

Exact text from the filing

On May 26, 2026, Artelo Biosciences, Inc. (the “Company”) entered into an At The Market Offering Agreement (the “Sales Agreement”) with H.C. Wainwright & Co., LLC (the “Sales Agent”) to create an at-the-market equity program under which it may sell up to an aggregate of $6,530,000 of shares of the Company’s common stock

View on SEC.gov

38 material agreements filed in the last 30 days. Browse all material agreements →

ARTELO BIOSCIENCES, INC. filing history →

Source: SEC EDGAR

accession 0001640334-26-000973

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.